Directory of Peptide Formulation Plants

VISEN Pharmaceuticals (02561.HK) is an innovative biopharmaceutical company focusing on the endocrine field, licensed by Ascendis Pharma to introduce the TransCon technology platform. The company has independently developed a proprietary Dual-Chamber Device (DCD) platform, which separates lyophilized drugs and diluents into two chambers in the same cassette bottle, and bypasses and reconstitutes them in a pen syringe before use, that is, a typical 'dual-chamber cartridge' system, which is used for solubilized biological agents such as lonapegsomatropin. The company has cooperated with WuXi Biologics to promote the localization technology transfer of DCD preparations, and reached a strategic technical cooperation with Tofflon for dual-cavity lyophilized preparations: In August 2026, the dual-cavity lyophilized preparation production line equipment supplied by Tofflon completed factory acceptance (fat) and was delivered to the Chengdu factory, marking the start of the construction of localized commercial production capacity of 'lyophilization in dual-chamber cartridge'. This capability is oriented towards the reconstitution and administration of high-end biological agents, which can significantly improve patient compliance and drug safety, and is expected to become the first dual-cavity lyophilization technology in China.

Teva is a global leader in generic and specialty medicines headquartered in Petatikwa, Israel, with multiple production/R&D/logistics bases in Israel such as Kfar Saba, Neot Hovav, Jerusalem, Netanya, etc., and produces sterile injectables and other products at FDA/EMA GMP facilities. The secondary market report (IndexBox) listed it as one of the manufacturers of "producing double-cavity cassette bottle products for imitation injection", but this is a second-hand source and has not been directly confirmed by Teva's official website; its sterile injection and GMP facilities are authentic, and double-cavity cassette bottle filling should be considered suspicious and need to be verified with the manufacturer.

Thermo Fisher/Patheon operates a global sterile drug development and manufacturing facility of approximately 24,000 square meters in Joo Koon, Singapore (one of its six sterile sites worldwide). Existing capabilities include sterile liquid formulations, biopharmaceuticals, process development, clinical and commercial filling. The official website lists sterile lyophilized products, prefilled injection pens and prefilled cartridges as "Expansion/future (not currently available)" capabilities, that is, the cartridge filling is still in the planning stage of expansion and is not currently online. The base serves Asia Pacific and global supply chains.

OneSource Specialty Pharma is an Indian specialty drug/CDMO that focuses on drug-device combination products, providing the formulation, manufacturing and development of complex drugs, as well as the device assembly and testing of multiple injection pens/autoinjectors. Its CPHI data discloses that it has approximately 40 million cassettes + injection pen devices, 28 million PFS capacity at USFDA and EMA-approved plants, and supplies from both India and Poland. The company completed 18 successful inspections in 24 months and has the drug-device combination capability from development to commercial supply.

Maiva Pharma is a CMO/CDMO focused on sterile injections in India. In June 2026, a new 22-acre plant was opened in Shoolagiri, Tamil Nadu, with six production lines planned; the first phase has been put into production with a high-speed vial line, a combined PFS and cartridge line, and a freeze-drying line, all using isolator technology. Dosage forms cover vials, PFS, cassettes, suspensions and freeze-dried formulations for the global regulated market. The plant was built in accordance with international regulatory standards, strengthening the contract manufacturing capacity of aseptic injections and complex drug delivery systems in India.

Shantha Biologics, a vaccine and biopharmaceutical manufacturer in Hyderabad, India, signed a cartridge filling contract with Novo Nordisk in 2024/2025 to fill pre-filled cartridges with sterile pharmaceutical preparations and assemble them into injection pens for self-injection therapies such as insulin, GLP-1, antibodies, etc. Its automated bottle filling line has been approved by the FDA in the United States, publicly disclosing an annual capacity of about 130 million bottles for supply to the Novo Nordisk global supply chain, and plans to expand the manufacture of vaccines, biopharmaceuticals and sterile injectables. This capacity is a single cavity cassette bottle (insulin/GLP-1 pen type) filling, and the dual cavity cassette bottle is not specified in the public information.

Nipro Pharma is the top sterile injection contract manufacturer in Japan, with a product line covering ampoules, vials (liquid/powder/lyophilized), pre-filled pens (PFS), and the clearly listed “Dual chamber pre-filled syringes (Glass)” double-chamber pre-filled pens combination, complete with a double chamber bag (PLW). The company has production lines for lyophilized vials at the Ise and Odate plants (lyophilized lines are also available at the Vietnam plant), and a dedicated plant for high activity/anti-tumor to prevent cross-contamination. As a pharmaceutical company (not pure packaging material), Nipro both produces glass dual-cavity pre-filled syringe components and undertakes contract filling of combination products. Its production meets GMP/EU-GMP/JGMP/PIC/S standards and provides CDMO services for overseas markets (c-GMP, EU-GMP, JGMP, PIC/S).

BioCina is Australia's end-to-end CDMO (Adelaide + Perth, formerly Pfizer/Hospira, later merged by NovaCina in 2025) and claims to be one of the most comprehensive aseptic filling platforms in Asia Pacific: covering blow-fill seals (BFS), sterile vials, pre-filled pens, cartridges, cytotoxic and controlled substance filling. Its SA25 Cytiva robot isolator line fills vials, priming pens and cassettes (0.5–50 mL, 5 million + units per year). 50 + years of aseptic manufacturing history, 600 + approved products, 140 + countries of supply, regulatory approval by FDA, TGA, EMA, Health Canada, PMDA, ANVISA, etc.

ScinoPharm Taiwan is a sterile injection CDMO located in the Tainan Science Park. The scope of its sterile formulation filling consignment manufacturing services is clearly listed: sterile solution injection, lyophilized injection, pre-filled injection (PFS), cartridges, and injection pen combination system, with serialization and secondary packaging. The production line adopts a high-standard risk management and control disposable filtration filling component, which can meet the production specifications of anti-cancer drugs, high-risk drugs and biological drugs, and provides a complete lifecycle service from formulation development, process development (clinical trial to commercial batch), analytical method development and verification to commercial packaging.

Genovior Biotech is an integrated CDMO based in Taiwan that specializes in the production of peptide/protein biopharmaceuticals by microbial or recombinant fermentation processes, providing process development, amplification, formulation development and cGMP manufacturing. The official website specifies that its manufacturing capabilities include biopharmaceuticals, lyophilized injections, and prefilled syringe/cartridge for pre-clinical/clinical/commercial supply. Its Tainan Aseptic Factory holds PIC/S GMP/EU GMP (cGMP) certification and has been certified by the Taiwan FDA PIC/S GMP as a commercial factory for sterile pre-filled injection pens. It also has the ability to develop peg long-acting and microsphere preparations.

BioTechnique is a CRDMO of PSC Biotech, based in York, Pennsylvania, specializing in cytotoxic/therapeutic sterile injection filling and lyophilization, covering development to commercialization. Its aseptic platform supports vials (2R-100H), prefilled syringes, cartridges, and bags. The end-to-end process includes prescription, preparation, aseptic filtration, filling, half-pressure plug, optional freeze-drying, capping, QC, 100% visual inspection, and labeling packaging. It is equipped with multi-temperature (including -80°C and -190°C) 3PL warehousing. Freeze-drying cycle development is supported by freeze-drying experts. Suitable for small to large batches of complex injections such as high live, ADC, monoclonal antibody, suspension and vaccines.

Jubilant HollisterStier is a North American contract manufacturer/CMO with dual facilities in Spokane, Washington and Montréal, Quebec, Canada, providing sterile filling (clinical to commercial), lyophilization, ophthalmology and ointment manufacturing. The Spokane plant has 2–100 mL vials, an isolator filling line, and a lyophilizer, with an annual capacity of about 60 million vials (Line 4 is expected to start production in 2026); the Montréal plant supports small batch aseptic filling and lyophilization. The official website lists containers containing vials, cartridges, and ampoules. It is recognized by FDA, EMA, PMDA, Health Canada, ANVISA and other regulations, serving 5 of the top 20 pharmaceutical companies in the world.

Gram is a sterile injection CDMO based in Grand Rapids, Michigan that focuses on sterile filling of liquids and lyophilized vials, syringes, cartridges. It has 5 GMP plants (about 450,000 sq ft), 3 of which are designed according to Annex 1; the filling lines are all equipped with isolator technology. Sterile Filling Facility Two is equipped with a groninger 10-head syringe/cartridge filling line (SKAN isolator), with a cartridge specification of 1.5-20 mL, with an annual capacity of more than 50 million bottles/syringes; Facility One has an annual capacity of more than 80 million vials and more than 10 million syringes/cartridges, and is equipped with an IMA lyophilizer. In 2026, it was announced that $100 million would be invested in the expansion of the fifth filling line and plant to strengthen the production capacity of commercial-grade prefilled syringes and cartridges. Have FDA/EU approved production lines, controlled substances and formulation capabilities (up to 1,000 L).

Kindeva is a CDMO dedicated to injection, inhalation and transdermal drug delivery. Formerly known as 3M drug delivery business, Kindeva has factories in Bridgeton, Missouri (155,000 sq ft sterile operating space, about 11,000 sq ft filling room) and Maryland Heights, providing aseptic filling (isolator technology) of vials, prefilled syringes, and cartridges, with an annual capacity of more than 150 million, covering small molecules, biopharmaceuticals, polypeptides, and vaccines. Its cartridge filling line is Syntegon 18 heads, 1–10 mL, 20-50 million units per year. Kindeva publicly disclosed that it developed the concept of dual-chamber/dual-cartridge and completed the proof-of-concept: lyophilized drug product is stored separately from the liquid medium, mixed/reconstituted in a syringe and injected (for particle/nanoparticle suspension administration) before use.

Berkshire Sterile Manufacturing (BSM) is a cGMP aseptic filling CMO based in Lee, Massachusetts, focused on clinical and small batch commercial aseptic injections. Its sterile filling line is 100% isolator technology, which can fill vials, syringes, cartridges and custom containers, and explicitly provide dual chamber liquid/liquid and liquid/lyo (double chamber liquid-liquid and liquid-lyophilized) filling and lyophilization, all in the isolator. Services also include prescription development, lyophilization development, analytical method development and validation, and terminal steam sterilization. In 2022, its OEM apomorphine hydrochloride card bottle anda was approved by the FDA as the first commercial product. There are 3 filling lines, with commercial freeze-dried batches of up to 90,000 units/batch.

Lyophilization Technology Inc. (LTI) is a CDMO located in Warminster, Pennsylvania, that focuses on lyophilization throughout the process, covering prescription development and process amplification to clinical trial drug production. Its official website explicitly provides the filling and lyophilization of dual chamber cartridges & syringes (single or dual chamber cassettes/syringes) to support the processing of dual chamber containers for clinical trial samples in development laboratories and sterile workshops. Containers cover vials, cartridges, syringes, lyophilizers 8–48 ft ², batches up to 75 L; cGMP, US and EU compliant, BSL-2 and high live/cytotoxic drug containment capacity, and DEA controlled substance licensing. LTI serves more than 500 biotechnology and pharmaceutical customers and is one of the few CDMOs in North America that has publicly stated that it can be used for dual-cavity cassette freeze-drying bottles.

PCI Pharma Services is a globally integrated CDMO offering aseptic filling, lyophilization and advanced dosing/combination product assembly packaging from development to commercialization. The core of North America is Bedford Campus, New Hampshire (50,000 sq ft sterile filling + freeze-drying plant in 2025, double 40 m ² freeze-dryer, isolator filling line, up to 300,000 vials, 400 vpm) and Philadelphia HQ. Its sterile filling covers vials, prefilled syringes, autoinjectors, on-body injectors and cartridges for pens, supporting monoclonal antibodies, oligonucleotides, polypeptides, etc. PCI has 30 GMP facilities, 5,500 + employees, and 90 + product launches per year to provide end-to-end injection solutions.

Swiss CDMO giant, biopharmaceutical and sterile injection (drug product) capacity covers Switzerland Stein, Visp, Basel. Its filling line supports liquid and lyophilized vials, pre-filled syringes (PFS) and cartridges, using isolator technology and innovative lyophilization; the Stein base is expanding the large-scale biopharmaceutical DP facility (about 20,000 m ², CHF 500 million investment, put into production in 2027), adding cassette/pre-filled syringe filling and vial lyophilization capabilities. Basel is a centre of excellence for process development and characterization. Through Annex 1 compliance, more than 150 biopharmaceutical DP technology transfers, serving monoclonal antibodies, bioconjugates, viral vectors, etc.

Catalent is the world's leading end-to-end CDMO, headquartered in New Jersey, with an 875,000 sq ft sterile biologics and filling plant in Bloomington, Indiana, deep plowing sterile prescription and filling, covering liquid/lyophilized vials, prefilled syringes, cartridges. The Bloomington plant includes a number of high-speed filling lines (vials, syringes, flexible cartridge lines), isolator technology, and freeze-drying capabilities, and has provided commercial filling for J&J's COVID-19 vaccines. Catalent also offers cartridges filling (single chamber) for injection pens. Its dual-chamber product, CosmoPod Duo, is a consumer health topical softgel (non-injectable). Catalent is FDA/cGMP compliant and serves 600 + mAbs, 80 + proteins and other biologics.

Ajinomoto Bio-Pharma Services is a globally integrated CDMO with facilities in Japan, India, Belgium, and the United States, providing small and large molecule APIs, oligonucleotides, peptides, ADC/HPAPI, and sterile filling services. Its aseptic fill-finish clearly covers liquid and lyophilized vials, pre-filled pens (PFS) and cartridges, and has lyophilization and pen system capabilities. Its San Diego high-speed multipurpose filling line “includes prefilled syringes, cartridges and vials” with isolator barrier technology and ready-to-use components. Both Ibaraki in Osaka, Japan and Visakha Pharmacity in India have set up sterile filling plants that have passed FDA, EMA, PMDA, MHRA, Health Canada, ISO 13485 and other certifications to serve biologics, peptides, oligonucleotides and highly active drugs.

Recipharm is a global CDMO headquartered in Sweden (17 plants, 8 countries), with North American aseptic capacity provided through the Advanced Bio facility in Watertown, Massachusetts (80,000 sq ft, plasmid DNA/mRNA/nanoparticle preparation + aseptic filling) and a strategic alliance with Exela Pharma Sciences in 2024 (Lenoir, North Carolina, FDA approved, with an annual capacity of over 100 million vials and prefilled syringes, covering ADCs, GLP-1, vaccines). The official website of Recipharm clearly provides cartridges high-speed aseptic filling (complex prescriptions such as high viscosity, liposomes, nanoparticles) and sterile lyophilisation. 2025–2026 Continuous investment to expand US aseptic filling capacity to serve clinical and commercial projects of customers in North America/Europe.

SMC Ltd is a 35 + year old pharmaceutical contract manufacturing and device services company that acquired the end-to-end aseptic fill/finish facility in Charlotte, North Carolina in 2024 to provide development, analysis, device manufacturing, filling, assembly and secondary packaging from laboratory to market. In September 2025, SMC signed a MoU with Credence MedSystems to install and validate clinical-scale GMP dual chamber filling equipment at the Charlotte, NC facility to support Credence's Sequential Liquid-Liquid DCS and Lyo-Liquid Reconstitution DCS (lyophilization-liquid reconstitution dual chamber system) products, with plans to expand to commercial scale. As a result, the SMC North American plant has the filling capacity of a dual-cavity resolving system.

European CDMO, dual headquarters in Pamplona, Spain (microbial/precision fermentation up to 20,000 L) and Basel, Switzerland (mass biomanufacturing up to 40,000 L). The sterile injection capacity covers vials, pre-filled syringes, cassettes, ampoules and lyophilized powder injections; the official website explicitly includes "dual-chamber systems" and "reconstitution-device interface" in its lyophilized injection and complex injection services, supporting the prescription, dilution compatibility, reconstitution, container compatibility and pharmaceutical combination documents of dual-chamber products. Provides sterile filling (isolator/RABS), freeze-drying process development, analytical methods and stability, GMP/GMP-like production and CMC documentation, suitable for the development of peptides, proteins, biopharmaceuticals and complex injections from early stage to commercialization.

Vetter is the world's leading sterile prefilled delivery system CDMO, headquartered in Germany, with a manufacturing facility (Vetter Pharma USA) in Skokie, Illinois (Chicago), USA, providing clinical-stage sterile filling. Vetter is a pioneer of dual-chamber technology, with its V-LK ® dual-chamber cartridge containing lyophilized powder in the anterior chamber and diluent in the posterior chamber, mixed before use, and dedicated to polypeptides/proteins/biologics that need to be resolved; there is also a Vetter Lyo-Ject ® dual-chamber prime syringe. The clinical filling line at the Skokie plant in the United States covers vials to dual-chamber syringes, using RABS isolation technology. Vetter has 21 sterile filling lines around the world, filling 234 million sterile injections in 2024, 80% of the projects involve complex biological drugs, and are FDA/cGMP compliant.

RX Peptide Lab (Shanghai) Co., Ltd. (RX Peptide Lab) is a contract manufacturer of peptides in Songjiang, Shanghai. The official product page 'Dual Chamber Cartridge' clearly provides' end-to-end custom manufacturing of the finished peptide dual-cavity cassette bottle system ': freeze-dried peptides and solvents are separated into two independent chambers and dissolved before use. Services include peptide formulation development, process development (including lyophilization cycle development and dual-chamber filling technology), aseptic filling combined with lyophilization, cassette bottle customization specifications and label packaging, QC (purity/titer/sterility/endotoxin/stability), and FDA/EMA/NMPA compliance support. Positioning partial cosmetic anti-aging and scientific research peptide (labeled' For research purposes only '), supporting clinical, cosmetic and scientific research applications, MOQ 500.

Lin Yang Biotechnology (Genovior, founded in Taiwan in 2015 and acquired in 2025) is a professional sterile injection drug CDMO, which provides process development, amplification and formulation development for global pharmaceutical companies under the international PIC/S GMP (cGMP, EU GMP) specifications. The 'Small-Scale Injection Manufacturing' service page of the official website clearly provides' high quality filling services for glass bottle liquid/lyophilized dosage forms, syringe injections, cassettes, and dual-chamber prefilled syringes and cassettes', and is manufactured in accordance with PIC/S GMP, EU and US FDA specifications; in addition, it provides drug lyophilization technology development, packaging material design, clinical random code labeling and packaging. It has the preclinical-clinical-commercial mass production capacity of biological APIs such as polypeptides/proteins and monoclonal antibodies and sterile biological injections. It has advanced factories and R&D bases in Hsinchu and Tainan, Taiwan. It is one of the few CDMOs in Asia that can actually carry out mass production of APIs and injections.

The Sion era is a biological CDMO enterprise co-founded by Sun Xiaofeng and Dr. Cui Shulin. Changchun Sion Biotechnology was founded in 2013, and Beijing Sion Future Biotechnology is an industrialization platform. The official website of 'About Us' clearly declares that it has a 'double-cavity cassette bottle filling service' and says that it is' the only company in China that can plan, design, produce and fill double-cavity and multi-cavity cassette bottles'. It has built a 'double-cavity cassette bottle process and filling platform' and a 'double-cavity cassette injection pen production platform'. The company has formed five major technology platforms (fermentation, purification and freeze-drying of genetically engineered bacteria, dual-cavity cassette bottle technology and filling, dual-cavity cassette bottle injection pen, biological ambient temperature technology, and microspheres), covering fermentation amplification, extraction and purification, freeze-drying molding, preparation production, and dual-cavity cassette bottle filling equipment, and providing biological CDMO services to the outside world. Varieties include recombinant human growth hormone, recombinant human smaglutide, exenatide, recombinant human insulin-like factor, human type 3 collagen, etc.

PharmaMing Bio (2269.HK) is the world's leading biopharmaceutical CRDMO. Its Chengdu Wenjiang Microbial Commercial Production Base plans 95,000 square meters, focusing on the large-scale production of DS and DP of recombinant proteins such as polypeptides, antibody fragments, enzymes, cytokines, etc., and will land the 'first dual-cavity lyophilized preparation production line in China', jointly built with Weisheng Pharmaceutical, supporting the Xilin bottle line, with an annual production capacity of more than 10 million preparations. It is expected that GMP will be put into production by the end of 2026. The dual-cavity cassette bottle (DCD) system is used for the pre-filled injection pen of the long-acting growth hormone lonapegsomatropin, and the lyophilized powder is mixed with the diluent separately and before use. The base is equipped with the EffiX™ Escherichia coli expression platform (yield > 15g/L), and the Wuxi, Shanghai, and Hangzhou bases can provide end-to-end services from strain development to commercialization. The quality system complies with FDA, EMA, NMPA and other cGMP, and has passed official verification in Europe, the United States and China many times, serving 900 + clinical and commercial projects worldwide.

Grand Pharmaceutical Group Limited (Hong Kong stock code 00512.HK), with a history dating back to 1939, is a technologically innovative international pharmaceutical company headquartered in Wuhan. Its business covers nuclear drug anti-tumor diagnosis and treatment, cardiovascular and cerebrovascular precision interventional diagnosis and treatment, respiratory and critical care, five senses, cardiovascular and cerebrovascular first aid, API plates and high-quality amino acids. The Group has 8 R&D centers around the world, more than 770 R&D personnel, and more than 133 research projects. It continues to promote the "Go Global" global innovation strategy and in-depth cooperation with innovative pharmaceutical products and scientific research institutions in the United States, Australia, Germany, Belgium and other countries. Its business segment includes the "API segment" and "high-quality amino acids". However, the official website mainly focuses on the fields of nuclear drugs, cardiovascular and cerebrovascular interventions, mRNA and other innovative pharmaceutical devices, and does not specifically introduce polypeptide APIs.

Wuhan Tiantianhao Biological Products Co., Ltd. has been deeply engaged in the health industry for more than 30 years, focusing on polypeptide technology, integrating raw material production, product research and development, intelligent manufacturing and global sales, and positioning "functional peptide global business application leader" and "peptide national standard setting enterprise". The company was formerly known as Wuhan Peptide Research Institute, which was founded in 1997; in 2008, it presided over the preparation of China's first national standard for polypeptide products, "Soybean Peptide Powder" (GB/T 22492-2008). The company has built Wuhan Peptide Research Institute and Provincial Peptide Engineering Technology Research Center, built a provincial engineering technology research center with Wuhan Light Industry University, and established a postgraduate training base with Wuhan University, forming a whole chain innovation system from basic research to the transformation of achievements. Peptide raw products include microbial peptides, plant peptides (soybean peptides, walnut peptides, corn oligopeptides, flaxseed peptides, rice peptides, etc.), animal peptides (collagen tripeptides, fish collagen peptides, albumin peptides, casein peptides, whey peptides, etc.), and "peptide components". A total of more than 100 invention patents have been applied for, more than 200 SCI/scientific papers have been published, and the products have served 170 million consumers worldwide. It has been certified by ISO9001, ISO22000, halal, FDA, SC and other systems, and has China Peptide Industrial Park ("Most Beautiful Factory"), using AI intelligent screening and live cell targeting technology to prepare high-purity functional peptides.

Wuhan Yuelai Health Industry Co., Ltd. (hereinafter referred to as Yuelai, twinklife) was founded in 2014 with a registered capital of 120 million yuan. It is a health industry enterprise oriented towards the cause of anti-aging. The company attaches importance to the research and development of polypeptides. It has set up a number of research units such as a polypeptide anti-aging laboratory, a polypeptide basic laboratory, a polypeptide functional application laboratory, a polypeptide product testing laboratory, and a polypeptide cytology laboratory. In 2019, it jointly established the "Anti-aging Nutrition and Health Research Center" with the China Health Promotion Foundation, Huazhong University of Science and Technology Tongji Medical College, and Hubei Provincial Center for Disease Control and Prevention. In 2021, it built a smart factory integrating intelligence, standardization, Internetization, etc. It is equipped with a 100,000-level GMP purification production workshop, with powder and liquid drinking bags as the production core. In 2024, its manufacturing plate Hubei Yuehai Biotechnology Co., Ltd., in conjunction with China Ocean University, Nanchang University and other units, issued the first "Collagen Tripeptide" group standard in China. The business covers health food, health food, cosmetics and personal care products. The products have passed CMA, CNAS, FDA and other certifications, serving more than 1 million consumers. Note: It is mainly based on the R&D and application of peptide health foods/cosmetics, and is not a large-scale API API API manufacturer.

Wuhan Newtop Biotech Co., Ltd., located in Wuhan, Hubei, is a pharmaceutical manufacturing enterprise integrating R&D, production, sales and service, focusing on organic chemistry and pharmaceutical chemistry, with its own R&D center and laboratory. The company mainly focuses on polypeptides and pharmaceutical raw materials, including Semaglutide, Tirzepatide, Retatrutide, Cagrilintide, GHK-Cu, Melanotan, Thymosin alpha-1, LL-37, Selank, Epitalon, etc., and provides peptide freeze-dried powder and raw materials. With peptide synthesis, purification and active ingredient separation capabilities, the production system has obtained GMP, ISO 9001, HSE and other quality certifications, and has a D-level (ISO 8)/C-level (ISO 7) clean workshop; products are mainly exported to Europe, the United Kingdom, the United States, Canada, Australia and other countries and regions.

Wuhan Vanz Pharm Inc.), located in Wuhan, Hubei Province, was established in 2011 (some B2B files are recorded as 2016). It is a API (API), pharmaceutical intermediates, fine chemicals, peptides and food additives that integrate R&D, production and sales. Its products are sold worldwide. The company has a R&D center of about 1000 square meters in Wuhan (including multiple synthesis laboratories, pilot amplification laboratories and analytical laboratories). The manufacturing base is equipped with 100L-5000L reactors, which can provide one-stop services from R&D to commercial production. With long-term cooperation from Shanghai Institute of Organic Chemistry and Wuhan University, it has completed more than 20 APIs and intermediates R&D. Business covers custom synthesis (CDMO/CMC orientation), API contract production, quality control and regulatory consulting. Note: The company uses small molecule APIs/intermediates and custom synthesis as its core business, and peptides is only one of its product categories, not a dedicated peptide API factory.

Wuhan Sanyang Kaitai Biotechnology Co., Ltd., located in Wuhan City, Hubei Province, was established in 2018 and is a biotechnology enterprise focusing on peptide synthesis, antibody preparation and protein expression. The company relies on the technical experience of the core team (each core member has been engaged in the industry for more than 10 years) to provide cost-effective scientific research service solutions for scientific research institutions and corporate customers. The core business includes: customized peptide synthesis (peptides of different lengths, amino acid sequences and purity levels can be synthesized according to customer requirements, and accompanied by HPLC and MS test reports), protein expression (prokaryotic/eukaryotic expression system, from gene synthesis, vector construction to purification one-stop), antibody preparation (high specificity, high affinity antibodies), and biological testing services such as ELISA and Western Blot. The company has peptide synthesis, purification, freeze-drying equipment and perfect process, which can be delivered in 3 days at the earliest, and is positioned as a high-tech scientific research service company. Note: Mainly research-grade customized peptide/antibody/protein services, not a large-scale production enterprise of API API APIs, and API certification such as GMP/DMF has not been seen.

Wuhan Renfukang Pharmaceutical Co., Ltd. was established in January 2016 with a registered capital of 150 million yuan. It is a subsidiary of the listed company Renfu Pharmaceutical Group (600079.SH) and a technology-based small and medium-sized enterprise. It is located in Wuhan East Lake New Technology Development Zone. The company is mainly engaged in drug production and research and development. It has four dosage form production lines: tablets, hard capsules, lyophilized powder injections and injections. In 2017, it obtained a drug production license and GMP approval for clinical drugs. In August 2019, it passed the FDA on-site audit and obtained FDA certification. As an open pharmaceutical preparation CMO/CDMO/mAh service platform, it focuses on the commissioned development and production of preparations (especially injection small batch clinical samples, orphan drugs, and precious concentrates), and provides integrated services at home and abroad from raw materials to formulations, clinical, BE, registration, and production.

Wuhan Moore Biotechnology Co., Ltd. was established in 2008 with a registered capital of 21.4824 million yuan. It is a high-tech enterprise specializing in the research and development of peptide biological new drugs. It is a national "double" project construction unit and a high-tech enterprise in Hubei Province. It has built the "Moore Biology — Wuhan University Active Substance Research and Development Center" and academician expert workstation. It has obtained more than 20 national invention patents and has undertaken 2 major national major new drug creation science and technology projects. The company has established a full-chain peptide drug research and development platform (peptide gene engineering expression/purification, molecular screening design and target research, biologic drug identification and analysis, new preparations, etc.), equipped with 180 sets of high-end equipment. By the end of 2025, it will put into production a 14,500 ㎡ digital GMP genetic engineering production platform and cell production platform that meets the requirements of GMP in China, the United States, and Europe. It can produce 200kg of simaglutide API and other genetically engineered peptide products annually, and is being inspected by the Hubei Provincial Pharmaceutical Administration for drug production licenses. Products include Simiglutide APIs and backbone, liraglutide, HPV-BVTAG protein, HBV-PreS1 protein, and engineering enzymes; provide CDMO customization services (mg to kg) such as molecular screening, design, expression, purification, identification, process development, and quality control of polypeptide drugs.

Leading Hitech (Wuhan) Co., Ltd.) is a private company located in Wuhan that provides import and export services such as modern agriculture, feed and food additives, and health nutrition raw materials. The entrepreneurial team has been in the industry for nearly 20 years and has obtained the agency rights of many well-known brands in China. The related products have FAMI-QS, GMP +, HACCP, ISO22000 and other certificates, which meet European and American standards. Products include functional lipids (glyceryl tributyrate, etc.), vegetable essential oils, preservatives, sweeteners, as well as micro-ecological, polysaccharides and other functional additives (Bacillus licheniformis, glutathione, L-carnitine, DHA&EPA, etc.), and provide international trade services such as factory audits, global procurement distribution, formulation and production.

Wuhan Hualong Biopharmaceutical Co., Ltd., formerly known as Wuhan Meishan Biochemical Pharmaceutical Factory established in 1985, was restructured into the current company in 2000. It is a high-tech pharmaceutical enterprise integrating R&D, production and sales. It has more than 300 employees (more than 200 professional and technical personnel at colleges and above, and 36 practicing pharmacists). The company focuses on the field of injection drugs, especially bio-peptide products, and is one of the top three biochemical pharmaceutical companies in the country. The annual production capacity is about 90 million units. In 2004, it passed the GMP certification as a whole. In 2020, it was certified as a "high-tech enterprise" and won the bid for centralized procurement of national drugs in 2023. The core products of polypeptides include terlipressin injection, thymosin/thymosin injection for injection, somatostatin for injection, bone peptide injection, transfer factor injection, etc., covering cardiovascular and cerebrovascular, immune, digestive and other systemic therapeutic drugs.

Wuhan Huadong Biotechnology Co., Ltd. was founded on June 28, 2011 by Dr. Zeng Jianhua of Tongji Medical College of Huazhong University of Science and Technology. It is a high-tech enterprise with Dr. as the core team. Relying on Tongji Medical College of Huazhong University of Science and Technology, Wuhan Biotechnology Research Institute and other institutions, it is committed to the research, development, production and sales of anti-aging pharmaceuticals, functional foods, diagnostic kits and innovative biological drugs. The company has a number of national patents and registered trademarks (including patents in the fields of preventing white hair and skin aging), has independently developed a world-class anti-aging active ingredient "reduced MSR", and has completed a 10 million yuan angel round of financing, and has built a provincial-level university-enterprise joint key laboratory with Hubei Second Normal College. Its "Huapeptide" brand products feature peptide active ingredients, but are generally positioned as anti-aging cosmetics and functional health products companies.

Wuhan Jiushengtang Biotechnology Co., Ltd. (Peptide Valley Jiushengtang) is a company specializing in the research, development, production and sales of bioactive peptides. It is known as the "originator" of bioactive peptides in China and the first company in China to realize the transformation, industrialization and industrialization of bioactive peptides. The company was founded by Zou Yuandong, "the father of Chinese peptides" and "the father of enzymatic polypeptides", with "enzymatic polypeptides" as the core technology, focusing on new peptide immunological agents such as 39-peptide peptides (oral liquid), and has 39-peptide US/Japanese patents, as well as a number of peptide patents such as wheat protein peptide, camellia seed protein peptide, walnut protein peptide, bitter melon polypeptide, and puerarinide. The company has built a production base in Wuhan Jiushengtang, positioning peptide industry pioneers, covering bioactive peptide (enzymatic peptide) raw materials and functional health products, and setting up a peptide museum and other popular science exhibitions.

Wuhan Jiuan Pharmaceutical Co., Ltd. was founded in 1951 (originally Wuhan No.2 Pharmaceutical Factory) and renamed in 1999. It is a high-tech enterprise that mainly produces generic drugs and integrates R&D, production and sales. It is located in Wuhan Pharmaceutical Industrial Park on the shore of Lake Thomson in Jiangxia District, Wuhan City. The company has built a large-volume, small-volume injection and pre-perfusion-sealed injection workshop that meets the GMP standards. It has more than 140 drug approval numbers (more than 150 in a word). The core products are clinical emergency rescue drugs (such as dopamine hydrochloride injection, dexamethasone sodium phosphate injection, magnesium sulfate injection, etc.). Many varieties are included in the national emergency rescue drug catalogue.

Wuhan Hubei Huntide Biotech Co., Ltd.), an innovative manufacturer of small molecule peptides under Jetide Health, is located in Wuhan Optical Valley Biocity and has a production base built according to industrial standards in Xintan Industrial Park, Wuhan Economic Development Zone. The company's team has an average of more than 10 years of experience in the pharmaceutical/biological field. It has built a peptide R&D center of about 800 ㎡ and a cGMP standard multi-function workshop, focusing on the synthesis of small peptides with 2–6 amino acids. The core technologies include liquid phase, solid phase, fragment and enzyme catalytic synthesis (especially liquid phase synthesis), and provide modification services such as C-terminal/N-terminal modification, disulfide bond/amide cyclization. Products range from polypeptide building blocks, intermediates to active/functional peptides and peptide derivatives (such as carnosine L-Carnosine, glutamine dipeptide, N-acetyl carnosine, Gly-His-Lys skin care peptide, etc.), and provide process development, custom synthesis, and OEM foundry (laboratory/pilot to commercial scale) for customers in the pharmaceutical, cosmetic, and food sectors. The parent company Jipeptide Biotechnology (founded in Wuhan in September 2012) has 200 acres of chemical land, 20,000 square meters of self-built plant, 4 industrialized production lines, and an annual production capacity of 1,000 tons of small molecule peptides, fully implementing GMP management.

Founded in 1998 and listed on the Shenzhen Stock Exchange (300199) in 2011, Hybio Pharmaceutical is one of the earliest listed peptide drug companies in China. It is a national high-tech enterprise, focusing on the research and development, production and marketing of peptide drugs and small nucleic acid drugs, and layout of "innovative drugs + generic drugs" and CRDMO services. The company has a national-level platform such as the "National Local Joint Engineering Laboratory of Peptide Drugs", undertakes a number of national projects, and has won the second prize of the National Technology Invention Award and other honors. The quality system has passed multi-country GMP/cGMP certification such as China NMPA, US FDA, EU EMA, Brazil ANVISA, Australia TGA, Indonesia BPOM, South Korea MFDS. The Wuhan subsidiary (Linkong Demonstration Park in Huangpi District) is a special API production base for polypeptides. It is designed and built in accordance with international cGMP standards and equipped with a fully automatic polypeptide synthesis and purification system. It has passed the official GMP certification of China/the United States/Australia, and is expanding its API production line, with the goal of building a world-class polypeptide API base. The peptide API has now been sold to more than 20 countries and regions, and the preparation has been sold to more than 90 countries and regions. It has cooperated with international pharmaceutical companies such as Ferring, Hikma, and 3SBio Mandi, and has been first imitated/approved by the FDA in the United States.

Founded in 1992 (initiated by seven shareholders such as Wuhan University in 2000) and listed on the gem of the Shenzhen Stock Exchange on August 8, 2017 (stock code: 300683), Wuhan Haite Biopharmaceutical Co., Ltd. is a high-tech biopharmaceutical enterprise targeting biologically innovative drugs. The main business is the production, sales, import and export of bioengineering products and freeze-dried powder injections. There are 25 existing production codes for biological products and chemical drugs, and more than 1,000 employees (76% of whom have a college degree or above). The company's park covers an area of 138,000 square meters, has a production plant that meets the GMP standard of 14,800 square meters, and has passed the national GMP certification. It has five technology platforms such as a postdoctoral workstation and a "Hubei Provincial Rare Disease Drug Engineering Technology Research Center". The product focuses on the nervous system and oncology field, and has been listed on the national market as a class I biologic new drug for injection of mouse nerve growth factor NGF (Jinluojie, nerve growth factor is a polypeptide) and a class of genetically engineered biologic new drug for injection of epnemine (CPT). The company also provides CRO/CMO/CDMO technical services to domestic and foreign pharmaceutical companies, covering peptide immunomodulatory and enhancement drugs, APIs and intermediates, and expanding in the fields of macromolecules, small molecule drugs and in vitro diagnostics.

Wuhan sqn Biotechnology Co., Ltd. claims to be a leading supplier of chemical raw materials and peptides in China, focusing on health peptides, beauty/cosmetic peptides and active raw materials. It claims to have a GMP factory and 15 years of supply experience. Its products are mainly weight loss, beauty, and anti-aging peptides (such as Smeglutide, Telpotin, GHK-Cu, Melanotan II, nad +, DSIP, SS-31, etc.). It provides OEM/ODM and customization, and relies on the global logistics network to sell to North America, Europe, Southeast Asia and other markets. Note: According to the enterprise information of the Made-in-China platform, the company is registered as a "Trading Company". It was established in 2024, with a scale of 1–49 people, a registered capital of 100,000 yuan, and no independent official domain name. It mainly conducts business through the B2B platform. Its GMP qualification and "manufacturer" positioning need to be carefully verified.

Chongqing Zhixia Chemical Co., Ltd. (related to Nanjing Chenruisheng Biomedical Technology) was established in September 2023. It is a small and micro enterprise, mainly engaged in the research and development and supply of polypeptide GLP-1 raw materials, representing products including Semaglutide, Tirzepatide and other polypeptide raw materials. The business model is factory, customization and service, and the products are mostly marked as "for scientific research or export only". The company announced a registered capital of 500,000 yuan, 10–50 employees, and an annual turnover of about 3-5 million yuan. The contact information is shared with Nanjing Chen Ruisheng (the same phone/email address), and is positioned as a peptide small molecule GLP-1 raw material supplier for the global scientific research and export market.

High-volume foreign trade foundries with stable purity ≥ 98%

ZhuoShang Bio/ExcelBio is a GMP-certified nutraceutical manufacturer founded in 2013, located in Luoyang, Henan Province, focusing on providing one-stop OEM/ODM solutions for global brands; with 30,000 m ² of FDA-registered factories (10 production lines with an annual output value of more than $100 million), supporting a minimum order of 500 pieces. Main proteins, polypeptides and custom peptides (such as GHK-Cu, GHK-Cu powder, etc.), protein powder, gummies, capsules, beverages, etc., provide full link services from R&D, procurement, production to logistics, and hold GMP, FDA, COA, HACCP, Halal and other certifications. Note: The company's self-built official website has not been retrieved. This profile is from the Made-in-China corporate store, which is a third-party trading platform information, for reference only.

Sichuan Ampelbo Biotechnology Co., Ltd. (Chengdu Boke Pharmaceutical Technology Co., Ltd., Chengdu) is a professional R&D, production and sales of amino acid derivatives (amino alcohols, amino aldehydes, N-methyl amino acids, amino acid tert-butyl esters, Boc/Fmoc/Cbz protected amino acids, benzyl esters, amino acid amides, etc.). It also provides polypeptides, piperidine derivatives and chiral amine series products. It can provide domestic and foreign customers with high-quality pharmaceutical intermediates and fine chemicals from grams, kilograms to tons. Its products are exported to Europe and North America. It is a small high-tech/trade-oriented enterprise (with a staff size of about 8–50 people). The polypeptide is one of its product lines, with a partial amino acid protecting group and a polypeptide side chain/intermediate direction.

Shenzhen Peptide Chuangsheng Technology Co., Ltd. is a pioneer supplier of high-quality active peptides (cosmetic peptides) based in Shenzhen and radiating the world. It focuses on molecular biology and AI-driven peptide structure-activity research to provide efficient, verifiable and sustainable active peptide raw material solutions for scientific research institutions, pharmaceutical groups, medical cosmetic institutions and functional skin care brands. It has a Peptide AI design system and a peptide professional-grade laboratory, with a raw material purity of 99.8% pharmaceutical grade, adopts a biological + chemical synthesis green process (zero solvent instead of DMF), and a transdermal rate of > 80%, which meets the EU ECOCERT, US FDA gras, Japan JHOSPA and other regulations; and provides customized peptide synthesis (minimum order of 100g, 3–6 weeks delivery). The product covers 100 cosmetic peptides with 9 major efficacy matrices (blue copper peptide GHK-Cu, acetylhexapeptide-8/aquirelin, palmitoyl pentapeptide-4, conopeptide, etc.), 100% made in China, and serves 100 + customers worldwide (European pharmaceutical giant, North American pure beauty brand, CJK head beauty group).

Shenzhen Jianxiang Biotechnology (JYMed/Jianyuan Pharmaceutical) is a CDMO enterprise specializing in polypeptides, providing polypeptide API R&D and GMP production from milligrams to tons. With 13 cGMP production lines and 85,000 L spps/LPPS reactor volumes, the Hubei base has an annual production capacity of 10 + tons and has passed FDA, NMPA, and EDQM inspections. Employees of 650 + are located in Shenzhen (7,000 ㎡ R&D center), Hubei (52,000 ㎡ API production base, OEB-5 isolation), and Shenzhen (formulation FDF base). Services cover custom synthesis, polypeptide API manufacturing (long chain, unnatural amino acids, conjugates), cosmetics/veterinary drugs/health peptides and CDMO, supporting 1 g R&D to 100 kg commercial batches. With 20 + years of experience in peptide chemistry and CDMO, we provide peptide intermediates, APIs and CDMO services to pharmaceutical companies worldwide.

Shenzhen Han Yu Pharmaceutical Co., Ltd. (listed on the Shenzhen Stock Exchange, 300199, listed in 2011) is a national high-tech enterprise specializing in the R&D, production and sales of polypeptide drugs and small nucleic acids. Founded in 1998, it is an early listed polypeptide drug enterprise in China. The company has built a national and local joint engineering laboratory for polypeptide drugs, a national public experimental center for innovative polypeptide drugs, and a national pilot technology platform for the preparation of polypeptide drugs. It has undertaken a number of national-level projects and won the second prize of the National Technology Invention Award. It has passed the GMP/cGMP certification in China, the United States, the European Union, Brazil, Australia, South Korea and other countries, and has four major production bases: Shenzhen Pingshan Preparation Base, Wuhan Peptide Featured API Base (through the China/United States/Australia GMP certification, which is being expanded), Gansu Chengji Pharmaceutical Intermediates Base, Yunnan Dali Industrial Hemp Base, etc., to open up the whole chain control from raw materials to drugs. The APIs are sold to 20 + countries and regions, and the preparations are sold to 90 + countries and regions. The polypeptide products include GLP-1 injections such as liraglutide, smeclutide, tirpotide, etc., atoxiban, etibapeptide, etc., and have CRDMO (custom R&D + custom production) capabilities. The monomer reactor capacity is 100L-10000L.

Main overseas small peptide brand OEM

Shanghai QYAOBIO Co., Ltd. (ChinaPeptides/QYAOBIO), founded in October 2008, is a technology-based enterprise focusing on peptide synthesis, protein expression, and antibody preparation. In China, peptide solid phase synthesis (SPPs) technology was adopted earlier. The company maturely mastered 300 + peptide special modification core technologies, and has branches and scientific research laboratories in Suzhou, Wuhan, and Ezhou; cumulatively serving more than 50,000 customers worldwide, covering more than 50 countries and China's Hong Kong, Macao, and Taiwan regions, of which more than 90% are biomedical research institutions and pharmaceutical companies such as universities, hospitals, laboratories, and research institutes. Has passed ISO 9001: 2015 quality system certification, > 99% peptide synthesis success rate, provide HPLC/MS report and optional endotoxin/salt type test, as soon as 3 days delivery; core business is peptide synthesis, protein expression and antibody preparation.

Focus on overseas Biohacking channels, mature composite peptide kits

Shaanxi Borui Xiangtai Pharmaceutical Co., Ltd. was established on February 25, 2022 with a registered capital of 5 million yuan and is located in Lianhu District, Xi 'an City. It is an innovative enterprise specializing in the R&D, production and sales of polypeptides and their derivatives. The company uses "amino acid synthesis peptide APIs, personalized precision medical customized peptides, biochemical extraction products and multi-component biochemical drugs" as its product positioning; the representative varieties of synthetic peptides include thymosin acetate, oxytocin, nootropic peptide, temorelin, sermorelin, tilbopeptide, retarutide, lanrein, triplelin, liraglutide, etc. According to the chemical platform information, the company is relatively small (1–10 employees, 1–5 R&D), mainly engaged in Retatrutide, TB500, BPC157, etc., and does not have an official website.

Nanjing Yuanpeptide Biotechnology Co., Ltd. (Yuanpeptide Biotechnology) was established in 2018 and is located in the Biomedical Valley/Zhongdan Ecological Life Science Industrial Park in Jiangbei New District of Nanjing. It is a science and technology-based small and medium-sized enterprise (selected as a science and technology-based small and medium-sized enterprise in Jiangsu Province in 2025) that focuses on the synthesis of scientific research peptides and customized services. The company has 46 employees, an independent research and development center and 900 square meters of sterile laboratory, 4 standardized peptide production lines, equipped with Waters LC-MS/MS, UPLC, automatic purification system, automatic lyophilization system and other precision instruments, with a peak monthly production capacity of about 3000 peptides. Stable synthesis of conventional linear peptides and 60 amino acid long peptides, 100 amino acid super long peptides, specializing in polydithiocyclic peptides, head and tail closed-loop peptides, book peptides, highly hydrophobic membrane penetrating peptides, D-type amino acid peptides, glycopeptides, lipopeptides and other complex structures; modified types cover phosphorylation, sulfonation, methylation, acetylation, pegylation, biotin labels, a variety of fluorescent labels (FITC/Cy series), isotope labels (13c/15N), protein cross-linking and more than 300 kinds. Service ranges from milligrams to kilograms, and long-term cooperation with universities and medical institutions such as Nanjing University, Fudan, Shanghai Jiaotong University, and West China Hospital.

Active spot merchants on B2B platforms, sending overseas directly in small batches

Founded in 2013 in Hefei, Cellmano Biotech Limited is a high-tech company focused on the research and industrialization of solid phase peptide synthesis methods. The company has been engaged in the R&D and manufacturing of solid-phase polypeptide synthesis since 2011. It has a R&D center that meets the requirements of solid-phase synthesis, lyophilization and purification, and a complete set of analytical and testing instruments. The synthesis records, purification methods and test reports of each batch of products are archived in detail. Its main business includes peptide intermediates, cosmetic peptides (cosmetic peptides), custom synthesis of peptides, and peptide CMO services. It can provide customized peptides from mg to kg, from crude to 98% purity, and establish more than 2,000 commonly used catalog peptides in stock (gradually improve inventory, deliver in as fast as one week) to serve customers around the world. Approximately 10–50 employees.

Hefei HeSheng Biotechnology Co., Ltd. was established in 2014 and is located in Hefei High-tech Zone. It is an innovative polypeptide biotechnology company with polypeptide technology as its core. It focuses on the customization, research and development, production and service of polypeptide-related products, and is committed to becoming an international polypeptide CRDMO integrating polypeptide scientific research and customization, drug polypeptide intermediates and impurity customization, peptide API production, drug polypeptide research and development and process development, and beauty polypeptide research and development and production. The factory area of the company is about 4,000 square meters, and there are polypeptide R&D and production workshops such as synthesis, purification and analysis, with a total planned annual raw material production capacity of 200 kg (powder). It has more than 100 patents (including 24 invention patents). The service covers research custom polypeptide synthesis (long peptide, difficult peptide, branch peptide), labeling (isotope, fluorescence), cyclic peptide (amide ring, disulfide ring, subscription peptide ring, thioether ring), modification (glycopeptide, phosphorylation, peg, etc.), deuterated service, and polypeptide drug impurity customization; GMP small test/pilot and amplification production (mg to kg grade) can be carried out.

Founded in 2014, Hangzhou Go Top Peptide Co., Ltd. (Go Top Peptide) is a national high-tech enterprise focusing on the R&D and production of polypeptides and related derivatives. It is the governing unit of the polypeptide branch of the China Biochemical Pharmaceutical Industry Association. The company has more than 4,000 square meters of polypeptide research and development center in Hangzhou, and has established two commercial polypeptide production bases in Shangyu and Anji, Zhejiang. It has a number of polypeptide production lines, large-scale polypeptide synthesis equipment, imported HPLC analysis and preparation equipment, and is equipped with a GMP standard clean laboratory. It has passed ISO9001: 2015 quality management system certification. Provides peptide customization, modification, catalogue peptides and scientific/pharmaceutical peptide products.

Harbin Jixianglong Biotechnology Co., Ltd. was established at the end of 2011 and is located in the Harbin Limin Development Zone. It covers an area of 23,000 square meters, 16,000 square meters of buildings, a registered capital of 18.31 million yuan, a net asset of 110 million yuan, and 260 employees (70 R&D). It is a national high-tech enterprise, Heilongjiang Specialized New SME and Synthetic Peptide Drug Technology Innovation Center. The company focuses on independent R&D and custom R&D and production of peptide drugs, forming a two-wheel drive pattern of peptide raw material sales and formulation R&D services (CRO). It has built a GMP-certified peptide raw material production workshop, equipped with more than 300 sets of equipment such as solid phase synthesizers, preparation liquid chromatography, lyophilizers, and HPLC. The company has a complete industrial chain of R&D, approval and production, and has obtained 10 API production approvals (the third in the country in terms of quantity) using its own technology; Smeglutide and Tirpotide have completed US DMF filings with the US FDA and obtained NDCs for sale in US pharmacies; it has 16 invention patents (including 5 compound patents).

1688 spot order supplier, suitable for trial order purchase

Fujian Genohope Biotech Co., Ltd. (Genohope Biotech) was co-founded by the World's Top 500 New Hope Group and Taiwan's well-known peptide company Genovior (now part of Polaris Pharma Group). It is located in the Biological and New Pharmaceutical Industry Zone on both sides of Putian, Fujian, and is positioned as a global R&D and production center for polypeptide products. The company has more than 20 years of industry experience, a team of more than 500 people, covering more than 50 countries, organized according to GMP specifications, equipped with glass reactors, freeze-drying lines, automatic filling lines and other equipment. HP Peptide API products cover GLP/polypeptide products such as tilbopeptide, smectin, tidoglutide, itecarbide, mastopeptide, lanrein acetate, and oral sterile water for injection. We provide peptide API supply and services to customers around the world.

Sinopep-Allsino Biopharmaceutical is a global supplier of commercial grade APIs and a full range of polypeptide/oligonucleotide CDMOs. Providing end-to-end CMC development and cGMP production from early R&D to commercialization for new drugs (NCE) and innovative pharmaceutical companies since 2009. The company's current production capacity of polypeptides is about 20–30 tons/year. It has built a large-scale GMP oligonucleotide (ASO, siRNA and GalNAc, AOC, liposome and other conjugates) production facility that can produce thousands of kilograms per year in Lianyungang, Jiangsu Province. At the same time, it has small molecule generic drugs and NCE commercial production capacity. The quality and regulatory system is mature. It has passed four FDA on-site inspections, strictly follows FDA and ich guidelines, and provides process development, analytical method development and verification, stability research, and global IND/NDA declaration support.